This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinbach, W. J.
Right arrow Articles by Perfect, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinbach, W. J.
Right arrow Articles by Perfect, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4922-4925, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4922-4925.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Interactions between Antifungals and Immunosuppressants against Aspergillus fumigatus Isolates from Transplant and Nontransplant Patients

William J. Steinbach,1* Nina Singh,2 Jackie L. Miller,3 Daniel K. Benjamin Jr.,1,4 Wiley A. Schell,3 Joseph Heitman,5,6,7 and John R. Perfect3

Division of Pediatric Infectious Diseases, Department of Pediatrics,1 Division of Infectious Diseases and International Health, Department of Medicine,3 Duke Clinical Research Institute,4 Department of Molecular Genetics and Microbiology,5 Department of Pharmacology and Cancer Biology,6 Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina,7 Infectious Disease Section, Veterans Affairs Medical Center, University of Pittsburgh, Thomas E. Stanzel Transplantation Institute, Pittsburgh, Pennsylvania2

Received 1 June 2004/ Returned for modification 5 July 2004/ Accepted 3 August 2004


arrow
ABSTRACT
 
We performed in vitro antifungal checkerboard testing on 12 Aspergillus fumigatus clinical isolates (6 transplant recipients and 6 nontransplant patients) with three antifungal agents (amphotericin B, voriconazole, and caspofungin) and three immunosuppressants (FK506, cyclosporine, and rapamycin). We were not able to detect a difference in calcineurin inhibitor antifungal activity against isolates from transplant recipients and nontransplant patients.


arrow
TEXT
 
The incidence of invasive aspergillosis (IA) (13, 23) has increased significantly in the last several decades, paralleling the increase in the number of immunocompromised patients. While there has been a recent expansion of the antifungal armamentarium against IA (32), optimal treatment remains elusive, and newer agents with novel mechanisms are desperately needed. The immunosuppressants cyclosporine (CsA), tacrolimus (FK506), and rapamycin all suppress T-cell proliferative responses. CsA and FK506 inhibit calcineurin, a Ca2+/calmodulin-dependent protein phosphatase important in cell signaling (4, 17), while rapamycin functions through a separate TOR signaling pathway (28). These immunosuppressants have revolutionized modern transplantation, but their role as potential antifungal agents is only beginning to be understood (3, 12). The calcineurin pathway has been shown to be critical in fungal survival and stress response in several fungi (26, 29), including in vitro antifungal activity against Saccharomyces cerevisiae, Candida albicans, and Cryptococcus neoformans (5-9, 25) and fungicidal synergism between calcineurin inhibitors and the normally fungistatic azole antifungals (19-22, 27).

We previously reported the inherent in vitro antifungal activities of CsA and FK506 against Aspergillus fumigatus, as well as a positive interaction between CsA or FK506 and caspofungin against A. fumigatus (31). These results highlight the potential role that inhibition of the calcineurin stress response pathway could play in the treatment of IA. Here we investigated the in vitro antifungal activity of calcineurin inhibition against A. fumigatus clinical isolates from transplant patients already receiving calcineurin inhibitors as part of their immunosuppressive regimen versus the antifungal activity against clinical isolates from patients who did not receive a transplant and have never received a calcineurin inhibitor. Since it is known that patients on calcineurin inhibitors can develop IA, it is important to examine the development of direct drug resistance as a failure to prevent IA.

Six strains of A. fumigatus from nontransplant patients and six strains of A. fumigatus from transplant recipients (Table 1) were used. The nontransplant A. fumigatus strains were all clinical isolates from patients with IA from Duke University Medical Center, and the transplant recipient A. fumigatus strains were all clinical isolates from patients with IA at the University of Pittsburgh.


View this table:
[in this window]
[in a new window]
  		TABLE 1. A. fumigatus clinical isolates from Transplant recipients and nontransplant patients

Amphotericin B (Fungizone; Bristol-Myers Squibb Co., New York, N.Y.), caspofungin (Cancidas; Merck & Co., Rahway, N.J.), and voriconazole (Vfend; Pfizer, Inc., New York, N.Y.) were obtained as powders and prepared as outlined in the National Committee for Clinical Laboratory Standards (NCCLS) M38-A document (24). Rapamycin was obtained from the National Cancer Institute, FK506 was supplied by Fujisawa Healthcare, Inc. (Deerfield, Ill.), and CsA was purchased from Alexis Corporation.

In vitro MIC testing with amphotericin B, voriconazole, caspofungin, and the immunosuppressants was performed by the NCCLS M38-A microdilution method (24), modified for diluting the five immunosuppressants, with Candida parapsilosis ATCC 22019 as an antifungal control as previously described (31). We used an MIC-0 endpoint (optically clear well) for voriconazole and amphotericin B and an MIC-2 endpoint (prominent growth reduction or a 50% reduction in optical density) for caspofungin and the immunosuppressants. Additionally, for caspofungin-treated wells, we reported the minimum effective concentration, which we defined as the formation of aberrant hyphal tips seen by microscopy (1).

We also performed a total of 108 checkerboard tests, one for each immunosuppressant with each antifungal for each of the 12 isolates. The fractional inhibitory concentration (FIC) of a drug was defined as the MIC of the drug given in a combination divided by the MIC of the drug alone. An FIC index (FICI) ({Sigma}FIC) is the sum of the two FICs of the individual drugs (11). An FICI value of <0.5 indicated synergy, values of 0.5 to 4 indicated indifference, and a value of >4 indicated antagonism. We used nonparametric methods (Wilcoxon rank sum) to generate P values. Analyses were completed using Stata 8.1 statistical software (Stata Corp., College Station, Tex.).

CsA and FK506 both showed consistent in vitro antifungal activity against all 12 A. fumigatus isolates (Table 2). Rapamycin showed excellent activity at 24 h (data not shown) but lost all antifungal activity by 48 h. This work confirmed that FK506 and CsA possess inherent in vitro antifungal activity against A. fumigatus as previously described (31). We were not able to detect a difference in the MICs for the transplant and nontransplant clinical isolates.


View this table:
[in this window]
[in a new window]
  		TABLE 2. In vitro 48-h MIC for antifungals and Nontransplant immunosuppressants against A. fumigatus isolatesa

Checkerboard microdilution assays (Table 3) with isolates from transplant recipients versus isolates from nontransplant patients detected no difference between the two groups of isolates. The antifungal plus immunosuppressant combination with the lowest FICI was caspofungin plus FK506, while the combinations of voriconazole and an immunosuppressant yielded higher FICIs. These results are similar to our previous studies with other strains of A. fumigatus (31). In the isolates tested, there was a general interaction indifference between the antifungals and immunosuppressants on the basis of FICI calculation.


View this table:
[in this window]
[in a new window]
  		TABLE 3. FICIs for antifungal plus immunosuppressant combinations against A. fumigatus isolates

Host immunosuppression is a well-documented risk factor for IA (23), and optimal management of immunosuppressant therapy is crucial in the treatment of IA in transplant recipients. There is a critical balance between maintaining immunosuppression to sustain the transplanted graft and increased immunosuppression predisposing the patient to opportunistic fungal infection.

This in vitro antifungal activity of calcineurin inhibitors may have clinical benefits. For instance, the use of CsA yielded a 54% decrease in the incidence of IA in 126 heart transplant patients (15). A study of liver transplant recipients with IA showed a significantly lower rate of disseminated (30 versus 62%) and central nervous system infection (0 versus 46%) in a cohort of patients who received FK506 (30).

There has been limited previous in vitro evaluation of calcineurin inhibitors against A. fumigatus (2, 14, 16, 18, 31). Transplant recipients are one of the highest risk patient groups to develop IA (10), and it is this group of patients who are generally already receiving calcineurin inhibitors as part of their immunosuppressive regimen. Since the calcineurin inhibitors are being used in patients who developed IA, it is possible to hypothesize several reasons for its failure as an antifungal. First, the immunosuppressive activity is greater than the direct antifungal activity, and the increased host immunosuppression outweighs the antifungal effect. Second, there is the potential inability to achieve sustained levels of calcineurin inhibitors in serum or tissue that are above the inhibitory concentration for Aspergillus. Third, there could be a rapid development of drug resistance to the anti-Aspergillus activity of the calcineurin inhibitors in vivo. In this study, we were not able to detect any evidence for the third possibility of rapid development of drug resistance, since the in vitro anti-Aspergillus activity of the calcineurin inhibitors was sustained in groups with or without exposure to FK506 or cyclosporine.

This study again demonstrates the inherent in vitro antifungal activity of calcineurin inhibitors against A. fumigatus. Importantly, this is the first study evaluating calcineurin inhibitors utilizing clinical isolates from transplant recipients who were receiving calcineurin inhibitors versus isolates from nontransplant patients who were not receiving calcineurin inhibitors. We were unable to detect a difference in antifungal activity in the isolates from the different groups of patients. One plausible explanation relates to small sample size; specifically, despite testing 108 checkerboard assays, we tested only a total of 12 isolates. Alternatively, these results could imply that preexposure to calcineurin inhibitors did not alter their in vitro antifungal activity against the clinical isolates.

The patients at highest risk for IA are often already on immunosuppressants, so determining the optimal combination and balance of immunosuppressive and antifungal activity to combat IA will be crucial. The calcineurin inhibitors in use at this time have similar in vitro activities in isolates from transplant recipients and nontransplant patients, suggesting that long-term exposure to these drugs did not decrease their antifungal activity. Despite this in vitro antifungal activity of the calcineurin inhibitors, patients receiving these agents developed and succumbed to this infection. Therefore, in our opinion, the focus for this area of antifungal drug development with calcineurin inhibitors is the development of nonimmunosuppressive inhibitors with more potent anti-Aspergillus activity.


arrow
ACKNOWLEDGMENTS
 
W.J.S. was supported by grant K12-HD00850, N.S. was supported by grant 1 R01 AI054719-01, D.K.B. was supported by grant NICHD 1 R03 HD42940-02, J.H. was supported by grant AI-50438, and J.R.P. was supported by grants P01-AI-449175 and AI-28388.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Division of Pediatric Infectious Diseases, Box 3499, Duke University Medical Center, Durham, NC 27710. Phone: (919) 684-6335. Fax: (919) 684-8902. E-mail: stein022{at}mc.duke.edu. Back


arrow
REFERENCES
 
    1
  1. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330.[Abstract/Free Full Text]
    2. 2
  2. Bell, N. P., C. L. Karp, E. C. Alfonso, J. Schiffman, and D. Miller. 1999. Effects of methylprednisolone and cyclosporine A on fungal growth in vitro. Cornea 18:306-313.[CrossRef][Medline]
    3. 3
  3. Blankenship, J. R., W. J. Steinbach, J. R. Perfect, and J. Heitman. 2003. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr. Opin. Investig. Drugs 4:192-199.[Medline]
    4. 4
  4. Cardenas, M. E., M. C. Cruz, M. Del Poeta, N. Chung, J. R. Perfect, and J. Heitman. 1999. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin. Microbiol. Rev. 12:583-611.[Abstract/Free Full Text]
    5. 5
  5. Cruz, M. C., M. Del Poeta, P. Wang, R. Wenger, G. Zenke, V. F. Quesniaux, N. R. Movva, J. R. Perfect, M. E. Cardenas, and J. Heitman. 2000. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob. Agents Chemother. 44:143-149.[Abstract/Free Full Text]
    6. 6
  6. Cruz, M. C., A. L. Goldstein, J. Blankenship, M. Del Poeta, J. R. Perfect, J. H. McCusker, Y. L. Bennani, M. E. Cardenas, and J. Heitman. 2001. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob. Agents Chemother. 45:3162-3170.[Abstract/Free Full Text]
    7. 7
  7. Cruz, M. C., A. L. Goldstein, J. R. Blankenship, M. Del Poeta, D. Davis, M. E. Cardenas, J. R. Perfect, J. H. McCusker, and J. Heitman. 2002. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J. 21:546-559.[CrossRef][Medline]
    8. 8
  8. Cruz, M. C., R. A. Sia, M. Olson, G. M. Cox, and J. Heitman. 2000. Comparison of the roles of calcineurin in physiology and virulence in serotype D and serotype A strains of Cryptococcus neoformans. Infect. Immun. 68:982-985.[Abstract/Free Full Text]
    9. 9
  9. Del Poeta, M., M. C. Cruz, M. E. Cardenas, J. R. Perfect, and J. Heitman. 2000. Synergistic antifungal activities of bafilomycin A1, fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743-873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:739-746.[Abstract/Free Full Text]
    10. 10
  10. Denning, D. 1998. Invasive aspergillosis. Clin. Infect. Dis. 26:781-805.[Medline]
    11. 11
  11. Eliopoulos, G. M., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
    12. 12
  12. Fox, D. S., and J. Heitman. 2002. Good fungi gone bad: the corruption of calcineurin. Bioessays 24:894-903.[CrossRef][Medline]
    13. 13
  13. Groll, A. H., P. M. Shah, C. Mentzel, M. Schneider, G. Just-Neubling, G. Huebling, and K. Heubner. 1996. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33:23-32.[CrossRef][Medline]
    14. 14
  14. High, K. P. 1994. The antimicrobial activities of cyclosporine, FK506, and rapamycin. Transplantation 57:1689-1700.[Medline]
    15. 15
  15. Hoflin, J. M., I. Potasman, J. C. Baldwin, P. E. Oyer, E. B. Stinson, and J. S. Remington. 1987. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann. Intern. Med. 106:209-216.
    16. 16
  16. Kontoyiannis, D. P., R. E. Lewis, N. Osherov, N. D. Albert, and G. S. May. 2003. Combination of caspofungin with inhibitors of the calciuneurin pathway attenuates growth in vitro in Aspergillus species. J. Antimicrob. Chemother. 51:313-316.[Abstract/Free Full Text]
    17. 17
  17. Liu, J., J. D. Farmer, Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815.[CrossRef][Medline]
    18. 18
  18. Lugardon, K., S. Chasserot-Golaz, A.-E. Kieffer, R. Maget-Dana, G. Nullans, B. Kieffer, D. Aunis, and M.-H. Metz-Boutigue. 2001. Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide. J. Biol. Chem. 276:35875-35882.[Abstract/Free Full Text]
    19. 19
  19. Maesaki, S., P. Marichal, M. A. Hossain, D. Sanglard, H. V. Bossche, and S. Kohno. 1998. Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. J. Antimicrob. Chemother. 42:747-753.[Abstract/Free Full Text]
    20. 20
  20. Marchetti, O., J. M. Entenza, D. Sanglard, J. Bille, M. P. Glauser, and P. Moreillon. 2000. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob. Agents Chemother. 44:2932-2938.[Abstract/Free Full Text]
    21. 21
  21. Marchetti, O., P. Moreillon, J. M. Entenza, J. Vouillamoz, M. P. Glauser, J. Bille, and D. Sanglard. 2003. Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob. Agents Chemother. 47:1565-1570.[Abstract/Free Full Text]
    22. 22
  22. Marchetti, O., P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard. 2000. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 44:2373-2381.[Abstract/Free Full Text]
    23. 23
  23. Marr, K. A., R. A. Carter, F. Crippa, A. Wald, and L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917.[CrossRef][Medline]
    24. 24
  24. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. NCCLS document M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    25. 25
  25. Odom, A., M. Del Poeta, J. R. Perfect, and J. Heitman. 1997. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob. Agents Chemother. 41:156-161.[Abstract]
    26. 26
  26. Odom, A., S. Muir, E. Lim, D. L. Toffaletti, J. R. Perfect, and J. Heitman. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16:2576-2589.[CrossRef][Medline]
    27. 27
  27. Onyewu, C., J. R. Blankenship, M. Del Poeta, and J. Heitman. 2003. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors in Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 47:956-964.[Abstract/Free Full Text]
    28. 28
  28. Rohde, J., J. Heitman, and M. E. Cardenas. 2001. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem. 276:9583-9586.[Abstract/Free Full Text]
    29. 29
  29. Sanglard, D., F. Ischer, O. Marchetti, J. Entenza, and J. Bille. 2003. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48:959-976.[CrossRef][Medline]
    30. 30
  30. Singh, N., R. K. Avery, P. Munoz, T. L. Pruett, B. Alexander, R. Jacobs, J. G. Tollemar, E. A. Dominguez, C. M. Yu, D. L. Paterson, S. Husain, S. Kusne, and P. Linden. 2003. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis. 36:46-52.[CrossRef][Medline]
    31. 31
  31. Steinbach, W. J., W. A. Schell, J. R. Blankenship, C. Onyewu, J. Heitman, and J. R. Perfect. 2004. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob. Agents Chemother. 48:1664-1669.[Abstract/Free Full Text]
    32. 32
  32. Steinbach, W. J., and D. A. Stevens. 2003. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin. Infect. Dis. 37(Suppl. 3):S157-S187.

Antimicrobial Agents and Chemotherapy, December 2004, p. 4922-4925, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4922-4925.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dannaoui, E., Schwarz, P., Lortholary, O. (2009). In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes. Antimicrob. Agents Chemother. 53: 3549-3551 [Abstract] [Full Text]  
  • Cramer, R. A. Jr., Perfect, B. Z., Pinchai, N., Park, S., Perlin, D. S., Asfaw, Y. G., Heitman, J., Perfect, J. R., Steinbach, W. J. (2008). Calcineurin Target CrzA Regulates Conidial Germination, Hyphal Growth, and Pathogenesis of Aspergillus fumigatus. Eukaryot Cell 7: 1085-1097 [Abstract] [Full Text]  
  • Cowen, L. E., Steinbach, W. J. (2008). Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryot Cell 7: 747-764 [Full Text]  
  • Li, Y., Sun, S., Guo, Q., Ma, L., Shi, C., Su, L., Li, H. (2008). In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J Antimicrob Chemother 61: 577-585 [Abstract] [Full Text]  
  • Sun, S., Li, Y., Guo, Q., Shi, C., Yu, J., Ma, L. (2008). In Vitro Interactions between Tacrolimus and Azoles against Candida albicans Determined by Different Methods. Antimicrob. Agents Chemother. 52: 409-417 [Abstract] [Full Text]  
  • Kontoyiannis, D. P., Lewis, R. E., Alexander, B. D., Lortholary, O., Dromer, F., Gupta, K. L., John, G. T., del Busto, R., Klintmalm, G. B., Somani, J., Lyon, G. M., Pursell, K., Stosor, V., Munoz, P., Limaye, A. P., Kalil, A. C., Pruett, T. L., Garcia-Diaz, J., Humar, A., Houston, S., House, A. A., Wray, D., Orloff, S., Dowdy, L. A., Fisher, R. A., Heitman, J., Albert, N. D., Wagener, M. M., Singh, N. (2008). Calcineurin Inhibitor Agents Interact Synergistically with Antifungal Agents In Vitro against Cryptococcus neoformans Isolates: Correlation with Outcome in Solid Organ Transplant Recipients with Cryptococcosis. Antimicrob. Agents Chemother. 52: 735-738 [Abstract] [Full Text]  
  • Steinbach, W. J., Cramer, R. A. Jr., Perfect, B. Z., Henn, C., Nielsen, K., Heitman, J., Perfect, J. R. (2007). Calcineurin Inhibition or Mutation Enhances Cell Wall Inhibitors against Aspergillus fumigatus. Antimicrob. Agents Chemother. 51: 2979-2981 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinbach, W. J.
Right arrow Articles by Perfect, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinbach, W. J.
Right arrow Articles by Perfect, J. R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»